Harmonizing COVID Vaccine Schedule Good Idea, But US FDA Should Remain Flexible, Advisors Say
Executive Summary
Vaccines and Related Biological Products Advisory Committee also said that more data is needed to determine the groups that potentially could receive more than one periodic vaccine booster.
You may also be interested in...
ACIP Backs Transition To Bivalent COVID-19 Vaccine, Flexibility On Number Of Annual Doses
The CDC panel supports transition away from the monovalent vaccine to simplify the schedule and reduce errors, but says more data is needed. Members disagree on whether children will need a primary series and favor the option for older adults and the immunocompromised to be vaccinated twice a year.
COVID-19 Vaccine Strain Updates Don’t Exactly Fit Flu Model
Manufacturers have different production timelines and US FDA advisory committee members worry a June strain selection may not fit the timing of COVID-19 case surges.
US FDA Investigating Concomitant Flu, COVID Vaccine Link To Stroke Safety Signal
No stroke risk has been identified, but FDA and CDC officials want to investigate whether concomitant administration of influenza and COVID-19 vaccines are related to the issue.